Efficacy and safety of progesterone receptor inhibitors used in the therapy of patients with simple and proliferating uterine myoma


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: to evaluate the efficiency and safety of ulipristal acetate therapy for uterine myoma in reproductive-aged patients with simple and proliferating uterine myoma. Subjects and methods. A prospective randomized trial of the efficacy of ulipristal acetate was conducted in 30 patients with simple (Group 1) and proliferating (Group 2) uterine myoma. Results. After three-month treatment, amenorrhea was observed in 70 and 90% of the patients in Group 1 and 2, respectively. Three months after treatment initiation, ultrasonography revealed reductions in the diameter of nodules by 27 and 47% in these groups, respectively. There was a decrease in median M-echo up to 4-5 mm in 80% of the patients in both groups; the endometrial thickness was as high as 8 mm in 10% and that increased up to 12-14 mm in 10%. Conclusion. The findings show that ulipristal acetate may be recommended as an agent for preoperative preparation in the groups of patients with both simple and proliferating uterine myoma.

全文:

受限制的访问

作者简介

Sergey Levakov

I.M. Sechenov First Moscow State Medical University

Email: levakoff@yandex.ru
MD, Professor, head of Department of Obstetrics and Gynecology

Oleg Zairatyants

A.I. Evdokimov Moscow State University of Medicine and Dentistry

MD, Professor, head of Department of Pathologic Anatomy

Ekaterina Borovkova

I.M. Sechenov First Moscow State Medical University

Email: E-maihKatyanikitina@maN.ru
MD, associate professor of Department of Obstetrics and Gynecology

参考

  1. Carlson K.J., Miller B.A., Fowler F.J. Jr. The Maine Women’s Health Study: I. Outcomes of hysterectomy. Obstet. Gynecol. 1994; 83(4): 556-65.
  2. Parker W.H. Uterine myomas: management. Fertil. Steril. 2007; 88(2): 255-71.
  3. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet. Gynecol. 2008; 112(2, Pt 1): 387-400.
  4. Stewart E.A. Uterine fibroids. Lancet. 2001; 357(9252): 293-8.
  5. Carlson K.J., Miller B.A., Fowler F.J. Jr. The Maine Women’s Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet. Gynecol. 1994; 83(4): 566-72.
  6. Marjoribanks J., Lethaby A., Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2006; (2): CD003855.
  7. Lefebvre G., Vilos G., Allaire C., Jeffrey J., Arneja J., Birch C. et al. The management of uterine leiomyomas. J. Obstet. Gynaecol. Can. 2003; 25(5): 396-418; quiz 419-22.
  8. Laughlin S.K., Hartmann K.E., Baird D.D. Postpartum factors and natural fibroid regression. Am. J. Obstet. Gynecol. 2011; 204(6): 496. e1-6.
  9. Peddada S.D., Laughlin S.K., Miner K., Guyon J.P., Haneke K., Vahdat H.L. et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc. Natl. Acad. Sci. USA. 2008; 105(50): 19887-92.
  10. Viswanathan M., Hartmann K., McKoy N., Stuart G., Rankins N., Thieda P. et al. Management of uterine fibroids: an update of the evidence. Evid. Rep. Technol. Assess (Full Rep). 2007; (154): 1-122.
  11. Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T. et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012; 366(5): 409-20.
  12. Сидорова И.С., Леваков С.А., Зайратьянц О.В., Коган Е.А., Унанян А.Л. Современный взгляд на патогенез миомы матки. Акушерство и гинекология. 2006; Приложение: 30-3. [Sidorova I.S., Levakov S.A., Zayrat’yants O.V., Kogan E.A. The modern view of the pathogenesis of uterine fibroids. Akusherstvo u ginekologiya / Obstetrics and Gynecology. 2006. (3): 30-37. (in Russian)]
  13. Зайратьянц О.В. Изменения эндометрия, ассоциированные с модулятором рецепторов прогестерона. Новый вид обратимых морфологических изменений эндометрия при терапии лейомиом матки препаратом Эсмия® (улипристала ацетат, фармацевтическая компания «Гедеон Рихтер»). Руководство для врачей-патологоанатомов и акушеров-гинекологов. М.; 2013. 30 с. [Zayrat’yants O.V. Endometrial changes associated with the progesterone receptor modulator. A new kind of reversible morphological changes of the endometrium in the treatment of uterine leiomyomas drug Esmiya® (Ulipristal acetate, pharmaceutical company „Gedeon Richter”). Guide for pathologists and obstetricians. M.; 2013. 30 p. (in Russian)]
  14. Williams A.R., Bergeron C., Barlow D.H., Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int. J. Gynecol. Pathol. 2012; 31(6): 556-69.
  15. Williams А., Glant М. PRM-Associated Endometrial Changes (PAEC). ESMYA® (ulipristal acetate). Pathologist’s guide. Medical Information Service Preglem S.A. Geneva, Switzerland; 2012.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##